---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-050269"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2024-12-16T23:59:59+00:00"
generated_at: "2026-05-29T03:14:13.469536+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health CEO Sandford steps down; Dr. Milligan interim CEO

## Summary
- CEO Nicole Sandford departs immediately for family health matter; remains as consultant for transition.
- President Dr. Sandra Milligan named interim CEO; nationwide search for permanent successor underway.
- Separation: $375,000 biweekly over 9 months plus $135,000 bonus upon fundraising or by Sept 30, 2025.
- Board cites Sandford's role in launching OvaWatch and securing $10M ARPA-H award for endometriosis test.

## SEC filing metadata
- accession: 0001493152-24-050269
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2024-12-16T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000149315224050269/0001493152-24-050269-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000149315224050269/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-050269
- JSON: https://secwatch.observer/filing/0001493152-24-050269.json
- Plain text: https://secwatch.observer/filing/0001493152-24-050269.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.